{"id":"corticosteroid-prednisone","safety":{"commonSideEffects":[{"rate":"10%","effect":"Weight gain"},{"rate":"5%","effect":"Insomnia"},{"rate":"5%","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Prednisone acts as a synthetic glucocorticoid receptor agonist, which leads to anti-inflammatory and immunosuppressive effects.","oneSentence":"Glucocorticoid receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:59.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Asthma"},{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT05789030","phase":"NA","title":"Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-01","conditions":"Autoimmune Diseases","enrollment":60},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06934915","phase":"EARLY_PHASE1","title":"Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Christopher John McDougle, M.D.","startDate":"2026-11","conditions":"Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder","enrollment":32},{"nctId":"NCT06388564","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-10-11","conditions":"Chronic Graft-versus-host-disease","enrollment":120},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT07287397","phase":"PHASE1, PHASE2","title":"Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS","status":"RECRUITING","sponsor":"Vector Y Therapeutics","startDate":"2025-12-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT06585774","phase":"PHASE3","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-21","conditions":"Chronic Graft-versus-host-disease","enrollment":240},{"nctId":"NCT05848011","phase":"PHASE2","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MacroGenics","startDate":"2023-09-28","conditions":"Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent","enrollment":154},{"nctId":"NCT04300556","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-08-06","conditions":"Solid Tumor","enrollment":182},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT04322357","phase":"PHASE2","title":"Twice Weekly Steroids and Exercise as Therapy for DMD","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-07-30","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":21},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT01648556","phase":"NA","title":"Research of Predictive Factors to Immune Thrombopenic Purpura","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2013-01-15","conditions":"Purpura Thrombopenic","enrollment":37},{"nctId":"NCT07100990","phase":"PHASE3","title":"Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-11","conditions":"Optic Neuritis, Myelitis, Myelitis, Transverse","enrollment":382},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07245732","phase":"PHASE4","title":"Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":220},{"nctId":"NCT03187743","phase":"NA","title":"Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-04-17","conditions":"Lupus Erythematosus, Systemic","enrollment":72},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT06246513","phase":"PHASE3","title":"A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-01-15","conditions":"Limb-girdle Muscular Dystrophy","enrollment":17},{"nctId":"NCT07440238","phase":"PHASE2","title":"Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-03-30","conditions":"Septic Arthritis","enrollment":200},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT07431060","phase":"NA","title":"Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2026-02-13","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":120},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT05898308","phase":"PHASE4","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-12-04","conditions":"Pemphigus, Dermatologic Disease","enrollment":133},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":"Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases","enrollment":45},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT05603468","phase":"PHASE4","title":"Effect of PRP vs Corticosteroid in Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-15","conditions":"Tendinopathy","enrollment":387},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT04844814","phase":"PHASE2","title":"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation","status":"SUSPENDED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-02","conditions":"Gout, Chronic Kidney Disease, Renal Transplantation","enrollment":204},{"nctId":"NCT07223580","phase":"PHASE4","title":"A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-23","conditions":"Ureteroscopy, Post Operative Pain","enrollment":90},{"nctId":"NCT07380152","phase":"PHASE1","title":"Corticosteroid Therapy in Pulmonary Sequelae of Covid-19","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-08-10","conditions":"COVID-19 Pulmonary Complications","enrollment":100},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT04305145","phase":"PHASE2","title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-31","conditions":"Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III","enrollment":42},{"nctId":"NCT06588348","phase":"EARLY_PHASE1","title":"Corticosteroid Effect on Achalasia Variant EGJOO","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor Research Institute","startDate":"2022-07-26","conditions":"Esophagogastric Junction Outflow Obstruction","enrollment":12},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT06040255","phase":"PHASE4","title":"Focal Cerebral Arteriopathy Steroid Trial","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2023-10-01","conditions":"Pediatric Stroke, Arteriopathy, Arterial Ischemic Stroke","enrollment":80},{"nctId":"NCT04474847","phase":"PHASE3","title":"Abatacept for the Treatment of Giant Cell Arteritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-03-29","conditions":"Giant Cell Arteritis","enrollment":78},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT07362693","phase":"","title":"A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-12-31","conditions":"ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA)","enrollment":50},{"nctId":"NCT06342544","phase":"PHASE3","title":"Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04-29","conditions":"Ocular Myasthenia Gravis","enrollment":128},{"nctId":"NCT06781944","phase":"PHASE3","title":"OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-10-23","conditions":"Primary Membranous Nephropathy","enrollment":144},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05468320","phase":"PHASE3","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":51},{"nctId":"NCT03128905","phase":"PHASE3","title":"Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis","status":"COMPLETED","sponsor":"Lille Catholic University","startDate":"2018-02-05","conditions":"Chondrocalcinosis","enrollment":111},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT06126380","phase":"PHASE2","title":"Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Eledon Pharmaceuticals","startDate":"2023-10-25","conditions":"Kidney Transplant Rejection","enrollment":132},{"nctId":"NCT05643638","phase":"PHASE2","title":"A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD","status":"RECRUITING","sponsor":"Cynata Therapeutics Limited","startDate":"2024-03-04","conditions":"Graft Versus Host Disease, Acute","enrollment":60},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT06591468","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","status":"ENROLLING_BY_INVITATION","sponsor":"Han Ying","startDate":"2024-10-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":244},{"nctId":"NCT02997605","phase":"PHASE4","title":"Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-01-31","conditions":"RheumatoId Arthritis","enrollment":102},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT01961843","phase":"NA","title":"Abiraterone Acetate for Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01-14","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT01780844","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-03-05","conditions":"Kidney Transplantation","enrollment":149},{"nctId":"NCT00748644","phase":"PHASE3","title":"Efficacy Study of Two Treatments in the Remission of Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Wegener Granulomatosis, Microscopic Polyangiitis","enrollment":117},{"nctId":"NCT06453694","phase":"PHASE2","title":"Efgartigimod for the Treatment of Acute Optic Neuritis","status":"RECRUITING","sponsor":"Anastasia Vishnevetsky, MD, MPH","startDate":"2025-08-12","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT03721965","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-12-31","conditions":"Acute Graft-versus-host Disease","enrollment":2},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT03790332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2018-11-19","conditions":"Chronic Graft Versus Host Disease","enrollment":59},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT03584516","phase":"PHASE2, PHASE3","title":"GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-01-17","conditions":"Chronic Graft-versus-host Disease","enrollment":155},{"nctId":"NCT06143891","phase":"PHASE3","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-23","conditions":"Chronic Graft Versus Host Disease","enrollment":260},{"nctId":"NCT04520451","phase":"PHASE2","title":"Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-08-22","conditions":"Immunoglobulin G4 Related Disease","enrollment":27},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":87},{"nctId":"NCT06729606","phase":"PHASE3","title":"Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":471},{"nctId":"NCT05276492","phase":"PHASE1","title":"Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-01-24","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":50},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT02784210","phase":"PHASE2","title":"Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2016-10-05","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT03545464","phase":"PHASE3","title":"COrticosteroids in acUte uRticAria in emerGency dEpartment","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-21","conditions":"Urticaria, Angiœdema","enrollment":137},{"nctId":"NCT03760835","phase":"PHASE4","title":"Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment","status":"RECRUITING","sponsor":"Federico II University","startDate":"2016-08-11","conditions":"Congenital Adrenal Hyperplasia","enrollment":150},{"nctId":"NCT02330952","phase":"PHASE4","title":"Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-10","conditions":"Pulmonary Disease, Chronic Obstructive (MeSH)","enrollment":189},{"nctId":"NCT06970080","phase":"PHASE4","title":"Therapeutic Relevance of Abnormal Airway Morphology in Asthma","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-02","conditions":"Asthma","enrollment":242},{"nctId":"NCT07159906","phase":"PHASE1, PHASE2","title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-08","conditions":"Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT01731561","phase":"PHASE3","title":"Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11-16","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Renal Limited Forms","enrollment":166},{"nctId":"NCT03139604","phase":"PHASE3","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-07-19","conditions":"Graft-versus-host Disease (GVHD)","enrollment":439},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":"Dermatomyositis","enrollment":62},{"nctId":"NCT05197842","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2022-02-22","conditions":"ANCA-associated Vasculitis","enrollment":93},{"nctId":"NCT06952686","phase":"PHASE3","title":"A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants","status":"WITHDRAWN","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2025-06-30","conditions":"Muscular Dystrophies, Limb-Girdle","enrollment":""},{"nctId":"NCT07067801","phase":"PHASE3","title":"Evaluation of Oral Corticosteroid Therapy in Idiopathic Sudden Unilateral Hearing Loss.","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-11","conditions":"Sudden Sensorineural Hearing Loss","enrollment":430},{"nctId":"NCT04461418","phase":"PHASE2","title":"Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-03-30","conditions":"Brain Metastases, Adult","enrollment":2},{"nctId":"NCT07039019","phase":"EARLY_PHASE1","title":"Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-06-04","conditions":"Pleuritis, Non-specific","enrollment":40},{"nctId":"NCT04047576","phase":"PHASE2, PHASE3","title":"Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis","status":"RECRUITING","sponsor":"Peking University International Hospital","startDate":"2018-07-01","conditions":"Retroperitoneal Fibrosis","enrollment":60},{"nctId":"NCT05921305","phase":"PHASE3","title":"Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-08-03","conditions":"Acute Graft Versus Host Disease","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Corticosteroid: Prednisone","genericName":"Corticosteroid: Prednisone","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a small molecule glucocorticosteroid used to treat various conditions, including chronic sinusitis, rhinosinusitis, nasal polyps, autoimmune diseases, and hemangioma. It is administered as an intervention in clinical trials, often in combination with other medications such as iguratimod or leflunomide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}